Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases

Urologia Internationalis

Volumn 80, Issue 2, 2008, Pages 129-133

  Nakashima, Jun ^a   Kikuchi, Eiji ^a   Miyajima, Akira ^a   Nakagawa, Ken ^a   Oya, Mototsugu ^a   Ohigashi, Takashi ^a   Murai, Masaru ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Endocrine therapy; Metastasis; Prognostic factors; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; ANTIANDROGEN; C REACTIVE PROTEIN; HEMOGLOBIN; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SURVIVAL RATE; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; BONE NEOPLASMS; C-REACTIVE PROTEIN; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 41149165635     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112601     Document Type: Article

References (21)

1. Okamoto M, Lee C, Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997;57:141-146.
2. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC: Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182-187.
3. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW: Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995;45:542-549.
4. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M: Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000;6:2702-2706.
5. Fearon KC, McMillan DC, Preston T, Winstanley FP, Cruickshank AM, Shenkin A: Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer. Ann Surg 1991;213:26-231.
6. Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, P'Eng F K, Chi CW: Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996;91:1417-1422.
7. Kodama J, Miyagi Y, Seki N, Tokumo K, Yoshinouchi M, Kobashi Y, Okuda H, Kudo T: Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999;82:107-110.
8. Japanese Urological Association and the Japanese Pathological Society: General Rule for Clinical and Pathological Studies on Prostatic Cancer, ed 2. Tokyo, Kanahara, 1992.
9. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195-202.
10. Jewett HJ: The present status of radical prostatectomy for stage A and B prostatic cancer. Urol Clin North Am 1975;2:105-124.
11. Atzpodien J, Royston P, Wandert T, Reitz M: Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003;88:348-353.
12. Goransson J, Jonsson S, Lasson A: Pre-operative plasma levels of C-reactive protein, albumin and various plasma protease inhibitors for the pre-operative assessment of operability and recurrence in cancer surgery. Eur J Surg Oncol 1996;22:607-617.
13. Nozoe T, Saeki H, Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001;182: 197-201.
14. Latif Z, McMillan DC, Wallace AM, Sattar N, Mir K, Jones G, Underwood MA: The relationship of circulating insulin-like growth factor 1, its binding protein-3, prostate-specific antigen and C-reactive protein with disease stage in prostate cancer. BJU Int 2002;89:396-399.
15. Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG: C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 2005;95:961-962.
16. Alexandrakis MG, Passam FH, Ganotakis ES, Sfiridaki K, Xilouri I, Perisinakis K, Kyriakou DS: The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol 2003;25:41-46.
17. Emrich LJ, Priore RL, Murphy GP, Brady MF: Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 1985;45:5173-5179.
18. McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC: Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006;77:127-129.
19. de Mello J, Struthers L, Turner R, Cooper EH, Giles GR: Multivariate analyses as aids to diagnosis and assessment of prognosis in gastrointestinal cancer. Br J Cancer 1983;48: 341-348.
20. Nozoe T, Matsumata T, Kitamura M, Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998;176:335-338.
21. Glass TR, Tangen CM, Crawford ED, Thompson I: Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003;169:164-169.